MediaPlanet and Dante Labs Team Up to Highlight the Role of Whole Genome Sequencing within Rare Diseases

NEW YORK (PRWEB) September 14, 2018

Today, Mediaplanet announces the launch of this September's edition of "Rare Diseases." This campaign will showcase the innovative work being done within rare diseases research, diagnostics, and will highlight what industry experts and patients see as potential future therapies for those living with rare diseases.

The print component of "Rare Diseases" is distributed within this weekend's edition of USA Today in New York, San Francisco, Los Angeles, Chicago, Boston, Seattle, Houston, with a circulation of approximately 250,000 copies and an estimated readership of 750,000. The digital component is distributed nationally, through a vast social media strategy, and across a network of top news sites and partner outlets. To explore the digital version of the campaign, click here.

There are approximately 7,000 rare diseases and disorders that affect 30 million people in the United States. 80% of rare diseases are genetic in origin, and because of the lack of awareness surrounding rare diseases, the average diagnostic journey is over 7 years. Genetic testing can help lead to an accurate and timely diagnosis, expediting treatment options for patients.

We are highlighting one of the supporters of our Rare Diseases campaign Dante Labs. Dante Labs is transforming genetics: their mission is to make advanced genomic testing accessible to everyone. Dante Labs want to empower people with knowledge and insights about their own genetic information so that they can live healthy, long and happy lives.
Dante Labs leverages only the best genetic testing technologies worldwide. They have a full portfolio of sequencing platforms, from benchtop to the factory-scale instruments that deliver the right level of speed, capacity and costs. By using Next Generation Sequencing (NGS) - the most powerful genetic testing technology they are able to tell their customers everything about their genetic map. NGS has been revolutionizing healthcare and enabling personalized medicine.

"The coverage Whole Genome Sequencing provides makes for an extremely informative tool" says Andrea Riposati, Co-Founder of Dante Labs. "It allows you to continuously learn of new variants in parallel with scientists and run additional analyses on your genomic data in the future. So, the next time you have the opportunity, choose Whole Genome Sequencing and you will be choosing an asset that can give back and an asset for life."
Their Whole Genome Sequencing (WGS) - Full DNA analysis For Rare and Hereditary Diseases test is available on their website, us.dantelabs.com, for $499.

This campaign was made possible with the support of National Organization for Rare Disorders (NORD), BERG, NFL Green Bay Packer Clay Matthews, CureDuchenne, PTC Therapeutics, Boehringer Ingelheim, Incyte, Strongbridge Biopharma, Progenics Pharmaceuticals, Horizon Pharma, Cytokinetics, Retrophin, Centogene, Dante Labs, Global Genes, Rare Disease United Foundation, Chloe's Fight Rare Disease Foundation, Rare & Undiagnosed Network, RUN's NBA Initiative, and Cheyanna's Champions 4 Children.

About Mediaplanet
Mediaplanet is the leading independent publisher of content marketing campaigns covering a variety of topics and industries such as Health, Education, Lifestyle, Business and Technology, and Corporate Social Responsibility. We turn consumer interest into action by providing readers with motivational editorial, pairing it with relevant advertisers and distributing it within top newspapers and online platforms around the world. Please visit http://www.mediaplanet.com for more on who we are and what we do.

Press Contact:
Sarah Wasser
sarah.wasser(at)mediaplanet.com
(646) 979-2831

Read the full story at https://www.prweb.com/releases/mediaplanet_and_dante_labs_team_up_to_highlight_the_role_of_whole_genome_sequencing_within_rare_diseases/prweb15764356.htm

You May Also Be Interested In

• 1899, LLC, Awarded Concessions Contract for 2024 Summer Season at Easton's Beach
• TransAlta Declares Dividends
• Asante Announces Correction to Press Release